Compared with xenografts from previously established cell lines, patient-derived xenografts may more faithfully recapitulate the molecular diversity, cellular heterogeneity, and histology seen in patient tumors, although other limitations of murine models remain. The ability of these models to inform clinical development and answer mechanistic questions will determine their ultimate use.
No takes yet. Share an insight, caveat, or question.
Kopetz et al. (2012) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: